Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01777776
Title Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Encorafenib

Encorafenib + Ribociclib

Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Colorado Dept of Oncology Aurora Colorado 80045 United States Details
Karmanos Cancer Institute Dept of Oncology Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Cancer Center Dept Oncology NY New York 90033 United States Details
Oregon Health & Science University Dept. of OHSU (3) Portland Oregon 97239 United States Details
Vanderbilt University Medical Center SC - Dept of Oncology . Nashville Tennessee 37232 United States Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Woodville South Australia 5011 Australia Details
Novartis Investigative Site Montreal Quebec H2X 3J4 Canada Details
Novartis Investigative Site Utrecht 3584CX Netherlands Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field